Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

Doxorubicin (DOX), a chemotherapeutic agent, induces a cardiotoxicity referred to as
doxorubicin-induced cardiomyopathy (DIC). This cardiotoxicity often limits chemotherapy for …

Clinical use of doxorubicin (DOX) is limited because of its cardiotoxicity, referred to as DOX-
induced cardiomyopathy (DIC). Mitochondria-dependent ferroptosis, which is triggered by …

Background Patients with dilated cardiomyopathy whose symptoms and cardiac function
have recovered often ask whether their medications can be stopped. The safety of …

Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

1–«МНОЦ МГУ им. МВ Ломоносова», 119192, Москва, Ломоносовский пр-кт, д. 27, корп.
10 2–ФГБОУ ВО «ПИМУ» МЗ РФ, 603950, Нижний Новгород, пл. Минина и Пожарского …

Nonischemic dilated cardiomyopathy (DCM) often has a genetic pathogenesis. Because of
the large number of genes and alleles attributed to DCM, comprehensive genetic testing …

Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer.
Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer …

Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …